All In Biotech

Free tool

FAERS Monitor: Ethamolin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019357 or its brand name (Ethamolin, Ethanolamine Oleate). Reports on generic versions are filed under their own applications.

Reports

18

Serious

18

100% of reports

Hospitalization

1

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • oesophageal varices haemorrhage5
  • portal vein thrombosis3
  • product use in unapproved indication3
  • off label use2
  • abdominal pain1
  • abdominal pain upper1
  • anaemia1
  • arterial haemorrhage1
  • ascites1
  • cataract1
  • disseminated intravascular coagulation1
  • dry eye1
  • essential thrombocythaemia1
  • gastrointestinal ischaemia1
  • haemorrhagic ascites1

Reports by year received

View as table
YearReports
20138
20151
20171
20183
20191
20202
20221
20251

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,141 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
gastrointestinal ischaemia14238.0628.51,055
haemorrhagic ascites14104.1608.81,021
essential thrombocythaemia13178.5471.8791
oesophageal varices haemorrhageSignal52697.61279.210,892
portal vein thrombosisSignal31086.0386.32,256
arterial haemorrhage11024.2152.3255
disseminated intravascular coagulation183.012.420
ascites139.75.99
dry eye123.43.55
cataract119.62.94
product use in unapproved indicationSignal314.15.025
anaemia16.10.91
abdominal pain upper15.70.81
abdominal pain15.00.70
off label use22.70.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.